Published in Nat Rev Endocrinol on August 14, 2012
Bioreactor technologies to support liver function in vitro. Adv Drug Deliv Rev (2014) 1.05
Physiological basis for the etiology, diagnosis, and treatment of adrenal disorders: Cushing's syndrome, adrenal insufficiency, and congenital adrenal hyperplasia. Compr Physiol (2014) 0.88
Metabolite profiling and pharmacokinetic evaluation of hydrocortisone in a perfused three-dimensional human liver bioreactor. Drug Metab Dispos (2015) 0.84
Developmental and contextual considerations for adrenal and gonadal hormone functioning during adolescence: Implications for adolescent mental health. Dev Psychobiol (2014) 0.84
Modulation of 11β-hydroxysteroid dehydrogenase as a strategy to reduce vascular inflammation. Curr Atheroscler Rep (2013) 0.83
Gene-metabolite expression in blood can discriminate allergen-induced isolated early from dual asthmatic responses. PLoS One (2013) 0.80
Inhibition of corticosteroid-binding globulin gene expression by glucocorticoids involves C/EBPβ. PLoS One (2014) 0.78
Serum cholesterol selectively regulates glucocorticoid sensitivity through activation of JNK. J Endocrinol (2014) 0.78
CBG: a cortisol reservoir rather than a transporter. Nat Rev Endocrinol (2012) 0.77
Plasma steroid-binding proteins: primary gatekeepers of steroid hormone action. J Endocrinol (2016) 0.77
Evidence for an immune signature of prenatal alcohol exposure in female rats. Brain Behav Immun (2016) 0.76
A soy-based phosphatidylserine/ phosphatidic acid complex (PAS) normalizes the stress reactivity of hypothalamus-pituitary-adrenal-axis in chronically stressed male subjects: a randomized, placebo-controlled study. Lipids Health Dis (2014) 0.76
New Roles for Corticosteroid Binding Globulin and Opposite Expression Profiles in Lung and Liver. PLoS One (2016) 0.75
Corticosteroid-binding globulin is a biomarker of inflammation onset and severity in female rats. J Endocrinol (2016) 0.75
Asn347 Glycosylation of Corticosteroid-binding Globulin Fine-tunes the Host Immune Response by Modulating Proteolysis by Pseudomonas aeruginosa and Neutrophil Elastase. J Biol Chem (2016) 0.75
Measurement of free glucocorticoids: quantifying corticosteroid-binding globulin binding affinity and its variation within and among mammalian species. Conserv Physiol (2015) 0.75
Gender-specific differences in hypothalamus-pituitary-adrenal axis activity during childhood: a systematic review and meta-analysis. Biol Sex Differ (2017) 0.75
Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA (2002) 16.37
Hydrocortisone therapy for patients with septic shock. N Engl J Med (2008) 15.85
Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. N Engl J Med (2005) 8.65
Measurements of serum free cortisol in critically ill patients. N Engl J Med (2004) 5.46
Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med (2008) 5.30
A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA (2000) 4.92
The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab (2008) 4.90
Stress and disorders of the stress system. Nat Rev Endocrinol (2009) 4.61
Visualization of glucocorticoid receptor translocation and intranuclear organization in living cells with a green fluorescent protein chimera. Proc Natl Acad Sci U S A (1996) 2.52
Ultradian hormone stimulation induces glucocorticoid receptor-mediated pulses of gene transcription. Nat Cell Biol (2009) 2.46
The free hormone hypothesis: a physiologically based mathematical model. Endocr Rev (1989) 2.44
Cortisol response in relation to the severity of stress and illness. J Clin Endocrinol Metab (2005) 2.19
Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab (1981) 2.07
Localisation of 11 beta-hydroxysteroid dehydrogenase--tissue specific protector of the mineralocorticoid receptor. Lancet (1988) 1.97
Transcortin: a corticosteroid-binding protein of plasma. II. Levels in various conditions and the effects of estrogens. J Clin Invest (1959) 1.77
The hepatoadrenal syndrome: a common yet unrecognized clinical condition. Crit Care Med (2005) 1.75
Adrenal insufficiency in liver disease - what is the evidence? J Hepatol (2007) 1.69
Salivary cortisol: a better measure of adrenal cortical function than serum cortisol. Ann Clin Biochem (1983) 1.63
Assessment of adrenal function in cirrhotic patients: salivary cortisol should be preferred. J Hepatol (2010) 1.60
Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11β-hydroxylase inhibitor metyrapone. Ann Clin Biochem (2011) 1.57
Use of saliva for monitoring unbound free cortisol levels in serum. Clin Chim Acta (1981) 1.49
Glucocorticoid therapy in the intensive care unit. N Engl J Med (2004) 1.48
Hormone binding globulins undergo serpin conformational change in inflammation. Nature (1988) 1.47
Clinical use of unbound plasma cortisol as calculated from total cortisol and corticosteroid-binding globulin. J Steroid Biochem (1987) 1.46
The crucial role of pulsatile activity of the HPA axis for continuous dynamic equilibration. Nat Rev Neurosci (2010) 1.45
Septic shock and sepsis: a comparison of total and free plasma cortisol levels. J Clin Endocrinol Metab (2005) 1.43
Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. Diabetes (2005) 1.26
Plasma free cortisol fraction reflects levels of functioning corticosteroid-binding globulin. Clin Chim Acta (2005) 1.23
Corticosteroid-binding globulin synthesis regulation by cytokines and glucocorticoids in human hepatoblastoma-derived (HepG2) cells. J Clin Endocrinol Metab (1997) 1.20
Interactions of sex hormone-binding globulin with target cells. Mol Cell Endocrinol (2009) 1.19
Molecular properties of corticosteroid binding globulin and the sex-steroid binding proteins. Endocr Rev (1990) 1.13
A role for corticosteroid-binding globulin in delivery of cortisol to activated neutrophils. J Clin Endocrinol Metab (1990) 1.12
Estimation of the percentage of free steroid in undiluted serum by centrifugal ultrafiltration-dialysis. J Biol Chem (1980) 1.11
Hormones in saliva: mode of entry and consequent implications for clinical interpretation. Clin Chem (1983) 1.11
11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation. J Clin Endocrinol Metab (2009) 1.10
Increases in steroid binding globulins induced by tamoxifen in patients with carcinoma of the breast. J Endocrinol (1978) 1.09
Utility of salivary cortisol measurements in Cushing's syndrome and adrenal insufficiency. J Clin Endocrinol Metab (2009) 1.08
Differential effects of insulin and insulin-like growth factor I on the production of plasma steroid-binding globulins by human hepatoblastoma-derived (Hep G2) cells. J Clin Endocrinol Metab (1995) 1.07
Cellular uptake of steroid carrier proteins--mechanisms and implications. Mol Cell Endocrinol (2009) 1.07
Corticosteroid-binding globulin: the clinical significance of altered levels and heritable mutations. Mol Cell Endocrinol (2009) 1.07
Factors influencing the adrenocorticotropin test: role of contemporary cortisol assays, body composition, and oral contraceptive agents. J Clin Endocrinol Metab (2007) 1.04
Steroid-protein interactions. Human corticosteroid binding globulin: some physicochemical properties and binding specificity. Biochemistry (1981) 1.04
Measurement of salivary cortisol concentration in the assessment of adrenal function in critically ill subjects: a surrogate marker of the circulating free cortisol. J Clin Endocrinol Metab (2007) 1.02
Molecular and structural basis of steroid hormone binding and release from corticosteroid-binding globulin. Mol Cell Endocrinol (2009) 1.02
Temperature-responsive release of cortisol from its binding globulin: a protein thermocouple. J Clin Endocrinol Metab (2010) 1.01
Novel human corticosteroid-binding globulin variant with low cortisol-binding affinity. J Clin Endocrinol Metab (2000) 1.01
Ultradian cortisol pulsatility encodes a distinct, biologically important signal. PLoS One (2011) 1.00
Radioimmunoassay and tandem mass spectrometry measurement of bedtime salivary cortisol levels: a comparison of assays to establish hypercortisolism. J Clin Endocrinol Metab (2007) 1.00
Adrenocortical dysfunction in liver disease: a systematic review. Hepatology (2012) 0.99
Measurement of serum free cortisol shows discordant responsivity to stress and dynamic evaluation. J Clin Endocrinol Metab (2007) 0.99
Specific binding of human corticosteroid-binding globulin to cell membranes. Proc Natl Acad Sci U S A (1986) 0.95
Reduced maternal corticosteroid-binding globulin and cortisol levels in pre-eclampsia and gamete recipient pregnancies. Clin Endocrinol (Oxf) (2007) 0.95
Familial corticosteroid-binding globulin deficiency due to a novel null mutation: association with fatigue and relative hypotension. J Clin Endocrinol Metab (2001) 0.95
Molecular studies of corticosteroid binding globulin structure, biosynthesis and function. J Steroid Biochem Mol Biol (1991) 0.95
The influence of the route of oestrogen administration on serum levels of cortisol-binding globulin and total cortisol. Clin Endocrinol (Oxf) (2007) 0.94
Salivary cortisone is a potential biomarker for serum free cortisol. J Clin Endocrinol Metab (2010) 0.93
Transcortin Leuven: a variant of human corticosteroid-binding globulin with decreased cortisol-binding affinity. J Biol Chem (1982) 0.93
Decreased immunoreactivity and binding activity of corticosteroid-binding globulin in serum in septic shock. Clin Chem (1989) 0.93
The effects of supraphysiological doses of corticosteroids in hypotensive liver failure. Liver Int (2003) 0.92
Localization of 11 beta-hydroxysteroid dehydrogenase type II in human epithelial tissues. J Clin Endocrinol Metab (1996) 0.91
Assessment of adrenal function in cirrhotic patients using concentration of serum-free and salivary cortisol. Liver Int (2011) 0.91
Characterising adrenal function using directly measured plasma free cortisol in stable severe liver disease. J Hepatol (2010) 0.90
Direct assessment of peripheral pharmacokinetics in humans: comparison between cantharides blister fluid sampling, in vivo microdialysis and saliva sampling. Br J Clin Pharmacol (1998) 0.89
Real-time free cortisol quantification among critically ill children. Pediatr Crit Care Med (2011) 0.89
Corticosteroid-binding globulin and free cortisol in the early postoperative period after cardiac surgery. Clin Biochem (1999) 0.89
Development of a flow cytometric assay to study glucocorticoid receptor-mediated gene activation in living cells. Steroids (2003) 0.88
Free cortisol index as a surrogate marker for serum free cortisol. Ann Clin Biochem (2002) 0.88
Transport of steroid hormones: interaction of 70 drugs with testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab (1981) 0.88
Novel corticosteroid-binding globulin variant that lacks steroid binding activity. J Clin Endocrinol Metab (2010) 0.88
Improved ultrafiltration method for determining unbound cortisol in plasma. Clin Chem (1980) 0.87
Glucocorticoid and estrogen regulation of corticosteroid-binding globulin production by rat liver. Am J Physiol (1979) 0.87
Decreased corticosteroid-binding globulin in burn patients: relationship with interleukin-6 and fat in nutritional support. Crit Care Med (1998) 0.87
Variability in hydrocortisone plasma and saliva pharmacokinetics following intravenous and oral administration to patients with adrenal insufficiency. Clin Endocrinol (Oxf) (2007) 0.86
Free cortisol index: a rapid and simple estimation of free cortisol in human plasma. J Clin Endocrinol Metab (1975) 0.86
The free hormone hypothesis. Distinction from the free hormone transport hypothesis. J Androl (1992) 0.86
Corticosteroid-binding globulin regulates cortisol pharmacokinetics. Clin Endocrinol (Oxf) (2011) 0.86
Performance characteristics of five automated serum cortisol immunoassays. Clin Biochem (2004) 0.85
Does cantharides blister fluid provide access to the peripheral compartment? Eur J Clin Pharmacol (1982) 0.85
Mitotane has an estrogenic effect on sex hormone-binding globulin and corticosteroid-binding globulin in humans. J Clin Endocrinol Metab (2006) 0.85
Comparison of total and salivary cortisol in a low-dose ACTH (Synacthen) test: influence of three-month oral contraceptives administration to healthy women. Physiol Res (2008) 0.84
Specific steroid-binding glycoproteins of human blood plasma: novel data on their structure and function. J Steroid Biochem (1990) 0.83
CBG Santiago: a novel CBG mutation. J Clin Endocrinol Metab (2011) 0.83
Differences between concentrations of salivary cortisol and cortisone and of free cortisol and cortisone in plasma during pregnancy and postpartum. Clin Chem (1990) 0.82
Factitious Cushing's syndrome: discovery with use of a sensitive immunoradiometric assay for corticotropin. Endocr Pract (2004) 0.82
Serum regulates cortisol bioactivity by corticosteroid-binding globulin-dependent and independent mechanisms, as revealed by combined bioassay and physicochemical assay approaches. Clin Endocrinol (Oxf) (2011) 0.82
Free serum cortisol: quantification applying equilibrium dialysis or ultrafiltration and an automated immunoassay system. Clin Chem Lab Med (2007) 0.82
Detection of corticosteroid binding globulin in parotid fluids: evidence for the presence of both protein-bound and non-protein-bound (free) steroids in uncontaminated saliva. Acta Endocrinol (Copenh) (1988) 0.82
Salivary and free serum cortisol evaluation. Mil Med (2010) 0.82
The coming of age of liquid chromatography coupled to tandem mass spectrometry in the endocrinology laboratory. J Chromatogr B Analyt Technol Biomed Life Sci (2011) 0.82
Measurement of tissue cortisol levels in patients with severe burns: a preliminary investigation. Crit Care (2009) 0.82
High frequency of SERPINA6 polymorphisms that reduce plasma corticosteroid-binding globulin activity in Chinese subjects. J Clin Endocrinol Metab (2012) 0.81
Parotid fluid cortisol and cortisone. J Clin Invest (1969) 0.81
Steroid-protein interactions. Monogr Endocrinol (1971) 0.81
Identification and measurement of sex hormone binding globulin (SHBG) and corticosteroid binding globulin (CBG) in human saliva. Acta Endocrinol (Copenh) (1986) 0.81
Induction of adenylate cyclase in a mammary carcinoma cell line by human corticosteroid-binding globulin. Biochem Biophys Res Commun (1988) 0.81
Free cortisol in serum assayed by temperature-controlled ultrafiltration before fluorescence polarization immunoassay. Clin Chem (1993) 0.81
Transactivation assay for determination of glucocorticoid bioactivity in human serum. J Clin Endocrinol Metab (2002) 0.81
Free serum cortisol during the postoperative acute phase response determined by equilibrium dialysis liquid chromatography-tandem mass spectrometry. Clin Chem Lab Med (2003) 0.81
Hormonal effects on the secretion and glycoform profile of corticosteroid-binding globulin. J Steroid Biochem Mol Biol (2006) 0.80
Saliva and bloodspot cortisol: novel sampling methods to assess hydrocortisone replacement therapy in hypoadrenal patients. Clin Endocrinol (Oxf) (2004) 0.80
The nuclear receptor REV-ERBα mediates circadian regulation of innate immunity through selective regulation of inflammatory cytokines. Proc Natl Acad Sci U S A (2011) 2.38
Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res (2003) 1.88
Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nat Genet (2003) 1.58
Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11β-hydroxylase inhibitor metyrapone. Ann Clin Biochem (2011) 1.57
Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis (2012) 1.43
Identification of multiple, oxygen-stable HIF1 alpha isoforms, and augmented expression of adrenomedullin in rheumatoid arthritis. Clin Exp Rheumatol (2013) 1.40
Glucocorticoid sensitivity is determined by a specific glucocorticoid receptor haplotype. J Clin Endocrinol Metab (2004) 1.29
VEGF polymorphisms are associated with severity of diabetic retinopathy. Invest Ophthalmol Vis Sci (2008) 1.14
The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol (2011) 1.13
Endoscopic transsphenoidal pituitary surgery: evidence of an operative learning curve. Neurosurgery (2010) 1.11
Drug insight: selective agonists and antagonists of the glucocorticoid receptor. Nat Clin Pract Endocrinol Metab (2008) 1.07
Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire. J Clin Endocrinol Metab (2005) 1.05
Identification and functional analysis of SKA2 interaction with the glucocorticoid receptor. J Endocrinol (2008) 1.05
Steroid biomarkers and genetic studies reveal inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone reductase deficiency. J Clin Endocrinol Metab (2008) 1.04
Current concepts in glucocorticoid resistance. Steroids (2012) 1.03
NF-kappaB signalling is inhibited by glucocorticoid receptor and STAT6 via distinct mechanisms. J Cell Sci (2003) 1.02
Editorial: acromegaly--consensus, what consensus? J Clin Endocrinol Metab (2002) 1.01
Ultradian cortisol pulsatility encodes a distinct, biologically important signal. PLoS One (2011) 1.00
Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials. Eur J Endocrinol (2008) 0.98
Macrophage migration inhibitory factor gene polymorphism is associated with psoriasis. J Invest Dermatol (2004) 0.96
The role of the circadian clock in rheumatoid arthritis. Arthritis Res Ther (2013) 0.95
Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab (2005) 0.94
MNAR functionally interacts with both NH2- and COOH-terminal GR domains to modulate transactivation. Am J Physiol Endocrinol Metab (2008) 0.93
Expanding the spectrum of mutations in GH1 and GHRHR: genetic screening in a large cohort of patients with congenital isolated growth hormone deficiency. J Clin Endocrinol Metab (2009) 0.93
Pituitary-independent effect of octreotide on IGF1 generation. Eur J Endocrinol (2009) 0.91
Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. J Clin Endocrinol Metab (2003) 0.89
Glucocorticoid receptor over-expression promotes human small cell lung cancer apoptosis in vivo and thereby slows tumor growth. Endocr Relat Cancer (2010) 0.88
Seeking the optimal target range for insulin-like growth factor I during the treatment of adult growth hormone disorders. J Clin Endocrinol Metab (2003) 0.87
Current status and future opportunities for controlling acromegaly. Pituitary (2002) 0.87
A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study. Pharmacogenomics (2011) 0.84
Hypoxia and glucocorticoid signaling converge to regulate macrophage migration inhibitory factor gene expression. Arthritis Rheum (2009) 0.84
Treatment of acromegaly improves quality of life, measured by AcroQol. Clin Endocrinol (Oxf) (2007) 0.84
Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists. Clin Endocrinol (Oxf) (2013) 0.83
The circadian clock and asthma. Thorax (2013) 0.83
The methyltransferase WBSCR22/Merm1 enhances glucocorticoid receptor function and is regulated in lung inflammation and cancer. J Biol Chem (2014) 0.83
Novel therapeutic agents targeting the glucocorticoid receptor for inflammation and cancer. Curr Opin Investig Drugs (2008) 0.82
Case for the wider adoption of mass spectrometry-based adrenal steroid testing, and beyond. J Clin Endocrinol Metab (2014) 0.81
A ligand-specific kinetic switch regulates glucocorticoid receptor trafficking and function. J Cell Sci (2013) 0.81
Simultaneous measurement of cortisol and cortisone in human saliva using liquid chromatography-tandem mass spectrometry: application in basal and stimulated conditions. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 0.80
Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant. J Clin Endocrinol Metab (2006) 0.80
Pin1 promotes GR transactivation by enhancing recruitment to target genes. Nucleic Acids Res (2013) 0.80
The effect of type 1 IFN on human aortic endothelial cell function in vitro: relevance to systemic lupus erythematosus. J Interferon Cytokine Res (2014) 0.78
High levels of 150-kDa insulin-like growth factor binding protein three ternary complex in patients with acromegaly and the effect of pegvisomant-induced serum IGF-I normalization. Growth Horm IGF Res (2004) 0.77
The use of mass spectrometry to improve the diagnosis and the management of the HPA axis. Rev Endocr Metab Disord (2013) 0.77
The place of pegvisomant in the acromegaly treatment algorithm. Growth Horm IGF Res (2004) 0.77
IGF-I measurements in the monitoring of GH therapy. Pituitary (2007) 0.77
The effect of atorvastatin on serum lipoproteins in acromegaly. Clin Endocrinol (Oxf) (2005) 0.77
Glucocorticoids reduce inflammation in cystic fibrosis bronchial epithelial cells. Cell Signal (2012) 0.77
The pituitary gland and age-dependent regulation of body composition. J Clin Endocrinol Metab (2010) 0.76
Small vessel remodeling and impaired endothelial-dependent dilatation in subcutaneous resistance arteries from patients with acromegaly. J Clin Endocrinol Metab (2009) 0.76
Recent developments in the therapy of acromegaly. Expert Opin Investig Drugs (2006) 0.76
Measurement of salivary cortisol with liquid chromatography-tandem mass spectrometry in patients undergoing dynamic endocrine testing. Clin Endocrinol (Oxf) (2009) 0.76
Exon splice enhancer mutation (GH-E32A) causes autosomal dominant growth hormone deficiency. J Clin Endocrinol Metab (2007) 0.75
The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegaly. Eur J Endocrinol (2006) 0.75
Mass spectrometry for the endocrine clinic--much to digest. Clin Endocrinol (Oxf) (2013) 0.75
Clinical use of pegvisomant for the treatment of acromegaly. Treat Endocrinol (2003) 0.75
The challenges of reliance on insulin-like growth factor I in monitoring disease activity in patients with acromegaly. Horm Res (2004) 0.75
Pitfalls in the diagnosis of acromegaly. Horm Res (2004) 0.75
Thematic reviews. J Endocrinol (2011) 0.75
Medical treatment in acromegaly. Curr Opin Pharmacol (2003) 0.75
Commentary: Harmonizing growth hormone measurements: learning lessons for the future. J Clin Endocrinol Metab (2007) 0.75
Pituitary tumour therapy: using the biology. J Neuroendocrinol (2002) 0.75
The N-terminal transactivation domain of the glucocorticoid receptor mediates apoptosis of human small cell lung cancer cells. Genes Chromosomes Cancer (2014) 0.75